Licensed drug could reduce SARS-CoV-2 infection by up to 70 per cent, reveals study
Ovarian cancer: Potential therapeutic target identified
5 August 2021Zoonotic threats must be integrated into global health security planning, say experts
6 August 2021Licensed drug could reduce SARS-CoV-2 infection by up to 70 per cent, reveals study
A licensed drug normally used to treat abnormal levels of fatty substances in the blood could reduce infection caused by the SARS-CoV-2 virus by up to 70 percent, reveals a study in the laboratory by an international collaboration of researchers.
